Bio-Techne Corp (TECH): Price and Financial Metrics


Bio-Techne Corp (TECH): $366.35

-0.09 (-0.02%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TECH to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

TECH POWR Grades


  • TECH scores best on the Quality dimension, with a Quality rank ahead of 91.23% of US stocks.
  • TECH's strongest trending metric is Momentum; it's been moving down over the last 179 days.
  • TECH ranks lowest in Momentum; there it ranks in the 14th percentile.

TECH Stock Summary

  • With a one year PEG ratio of 3,075.75, BIO-TECHNE Corp is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 98.72% of US stocks.
  • TECH's current price/earnings ratio is 83.23, which is higher than 91.6% of US stocks with positive earnings.
  • With a price/sales ratio of 17.02, BIO-TECHNE Corp has a higher such ratio than 91.64% of stocks in our set.
  • Stocks that are quantitatively similar to TECH, based on their financial statements, market capitalization, and price volatility, are SLP, SPT, INSP, MTCH, and VSAT.
  • Visit TECH's SEC page to see the company's official filings. To visit the company's web site, go to www.bio-techne.com.

TECH Valuation Summary

  • In comparison to the median Healthcare stock, TECH's price/earnings ratio is 280.55% higher, now standing at 138.9.
  • TECH's price/sales ratio has moved up 9.9 over the prior 243 months.
  • TECH's price/sales ratio has moved up 9.9 over the prior 243 months.

Below are key valuation metrics over time for TECH.

Stock Date P/S P/B P/E EV/EBIT
TECH 2021-08-31 21.0 12.5 138.9 121.1
TECH 2021-08-30 21.2 12.6 140.8 122.7
TECH 2021-08-27 20.8 12.4 137.8 120.1
TECH 2021-08-26 20.7 12.3 137.3 119.6
TECH 2021-08-25 21.0 12.5 139.2 121.3
TECH 2021-08-24 22.3 12.3 102.8 85.7

TECH Growth Metrics

    Its 3 year net cashflow from operations growth rate is now at 31.71%.
  • The 2 year net income to common stockholders growth rate now stands at 60.37%.
  • Its year over year net cashflow from operations growth rate is now at 27.07%.
Over the past 34 months, TECH's revenue has gone up $326,980,000.

The table below shows TECH's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 1,029.575 346.313 210.53
2021-09-30 984.552 334.589 176.631
2021-06-30 931.032 352.164 140.41
2021-03-31 847.838 274.935 184.296
2020-12-31 798.966 249.538 174.946
2020-09-30 759.647 230.687 248.294

TECH's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • TECH has a Quality Grade of B, ranking ahead of 82.49% of graded US stocks.
  • TECH's asset turnover comes in at 0.44 -- ranking 101st of 682 Pharmaceutical Products stocks.
  • URGN, TMBR, and CRIS are the stocks whose asset turnover ratios are most correlated with TECH.

The table below shows TECH's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.440 0.680 0.188
2021-03-31 0.412 0.673 0.250
2020-12-31 0.392 0.666 0.240
2020-09-30 0.376 0.662 0.330
2020-06-30 0.372 0.654 0.302
2020-03-31 0.387 0.660 0.271

TECH Price Target

For more insight on analysts targets of TECH, see our TECH price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $549.60 Average Broker Recommendation 1.36 (Strong Buy)

TECH Stock Price Chart Interactive Chart >

Price chart for TECH

TECH Price/Volume Stats

Current price $366.35 52-week high $543.85
Prev. close $366.44 52-week low $335.02
Day low $358.43 Volume 197,500
Day high $372.48 Avg. volume 266,019
50-day MA $404.43 Dividend yield 0.35%
200-day MA $451.20 Market Cap 14.37B

Bio-Techne Corp (TECH) Company Bio


Bio-Techne Corporation is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. The company was founded in 1976 and is based in Minneapolis, Minnesota.


TECH Latest News Stream


Event/Time News Detail
Loading, please wait...

TECH Latest Social Stream


Loading social stream, please wait...

View Full TECH Social Stream

Latest TECH News From Around the Web

Below are the latest news stories about BIO-TECHNE Corp that investors may wish to consider to help them evaluate TECH as an investment opportunity.

BIO-TECHNE TO PRESENT AT THE CITI 2022 VIRTUAL HEALTHCARE CONFERENCE

Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the Citi 2022 Virtual Healthcare Conference on Thursday, February 24, 2022, at 10:15 a.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

Yahoo | February 22, 2022

BIO-TECHNE ANNOUNCES EXCLUSIVE DEVELOPMENT AND LICENSE AGREEMENT WITH THERMO FISHER SCIENTIFIC FOR ExoTRU® KIDNEY TRANSPLANT REJECTION ASSAY

Bio-Techne Corporation (NASDAQ: TECH) today announced an agreement with Thermo Fisher Scientific to exclusively complete development of and commercialize the ExoTRU kidney transplant rejection test developed by Exosome Diagnostics, a Bio-Techne brand.

Yahoo | February 22, 2022

BIO-TECHNE ANNOUNCES PUBLICATION OF NEW DATA DEMONSTRATING EXODX PROSTATE TEST CORRELATION WITH POST-PROSTATECTOMY PATHOLOGY OUTCOMES

Bio-Techne Corporation (NASDAQ:TECH) today announced an important publication in World Journal of Urology, entitled Pre–diagnosis urine exosomal RNA (ExoDx EPI score) is associated with post–prostatectomy pathology outcome. Principal investigator Dr. Alexander Kretschmer, urologist from Ludwig Maximilian University of Munich, Germany, and colleagues demonstrated utility of the ExoDx™ Prostate test, or EPI, to address limitations related to prostate biopsy sampling error, prostate biopsy bias as

Yahoo | February 14, 2022

BIO-TECHNE TO PRESENT AT THE 11th ANNUAL SVB LEERINK GLOBAL HEALTHCARE CONFERENCE

Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022, at 9:20 a.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

Yahoo | February 11, 2022

BIO-TECHNE AWARDED ON THE FORBES AMERICA'S BEST EMPLOYERS 2022 LIST

Bio-Techne Corporation (NASDAQ: TECH) today announced that it has been awarded on the Forbes list of America's Best Employers 2022. This prestigious award is presented by Forbes and Statista Inc., the world-leading statistics portal and industry ranking provider. The awards list can currently be viewed on the Forbes website.

Yahoo | February 10, 2022

Read More 'TECH' Stories Here

TECH Price Returns

1-mo -11.02%
3-mo -8.56%
6-mo -25.05%
1-year -10.24%
3-year 83.68%
5-year 241.94%
YTD -29.07%
2021 63.40%
2020 45.40%
2019 52.67%
2018 12.60%
2017 27.40%

TECH Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full TECH Dividend History

Continue Researching TECH

Want to see what other sources are saying about BIO-TECHNE Corp's financials and stock price? Try the links below:

BIO-TECHNE Corp (TECH) Stock Price | Nasdaq
BIO-TECHNE Corp (TECH) Stock Quote, History and News - Yahoo Finance
BIO-TECHNE Corp (TECH) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7979 seconds.